CORAL SPRINGS, Fla.--(BUSINESS WIRE)--Boca Pharmacal, Inc. made two major announcements today with the U.S. Food and Drug Administration granting its final approval for the Company’s Abbreviated New Drug Application (ANDA) to market its generic version of and Panlor®SS (Acetaminophen, Caffeine and Dihydrocodeine) and the signing of an exclusive marketing and distribution agreement with Tedor Pharma Inc. for Didrex® (Benzphetamine Hydrochloride). Boca Pharmacal also announced that the company plans to launch both products immediately.
